Effect of a dose-escalation regimen for improving adherence to roflumilast in patients with chronic obstructive pulmonary disease

Tuberculosis and Respiratory Diseases

Volumn 78, Issue 4, 2015, Pages 321-325

  Hwang, Hyunjung ^a   Shin, Ji Young ^a   Park, Kyu Ree ^a   Shin, Jae Ouk ^a   Song, Kyoung Hwan ^a   Park, Joonhyung ^b   Park, Jeong Woong ^a  

^a Gachon University   (South Korea)

^b Korea Worker's Compensation and Welfare Service   (South Korea)

Author keywords

Chronic obstructive; Clinical protocols; Phosphodiesterase 4 inhibitors; Pulmonary disease; Therapeutics

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; ROFLUMILAST;

ADVERSE DRUG REACTION; AGED; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FLUID INTAKE; HEADACHE; HUMAN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; PATIENT COMPLIANCE; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84953717807     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2015.78.4.321     Document Type: Article

References (11)

1. Hogg JC Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.
2. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366:563-71.
3. Lahu G, Facius A. Application of population pharmacokinetic modeling to explore the impact of alternative roflumilast dosing regimens on tolerability. Int J Clin Pharmacol Ther 2013; 51:832-6.
4. Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther 1999;12:131-5.
5. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001;297:280-90.
6. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.
7. Michalski JM, Golden G, Ikari J, Rennard SI. PDE4: a novel target in the treatment of chronic obstructive pulmonary disease. Clin Pharmacol Ther 2012;91:134-42.
8. Beghe B, Rabe K F, Fabbri LM. Phosphodiesterase-4 inhibitor therapy for lung diseases. Am J Respir Crit Care Med 2013; 188:271-8.
9. Giembycz MA, Newton R. Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 2011; (204):415-46.
10. Rabe K F. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011;163:53-67.
11. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94.